Search
Menu
Home
HTB
2002
December
HTB
December 2002
Contents
Meeting report
Protecting mothers from mono and dual therapies, and considering the value of Caesarean sections
Antiretrovirals
Boosted PIs: differences emerging in efficacy, tolerability, lipids
Europe steps in to protect discounted drugs for developing countries
Hair analysis may help determine drug levels, adherence and virological response
Disadvantage from prior nucleoside therapy persists for years during HAART
Treatment access
Europe steps in to protect discounted drugs for developing countries
Side effects
Perspectives on hormonal, mitochondrial and metabolic changes
IAS panel issues first guidelines for HIV and HIV drug-related metabolic complications (2002)
Side effects are a common cause of intentional non adherence to HAART
Coinfections and complications
PML-associated immune restoration disease associated with mortality
Basic science and immunology
Animal retroviral infections suggest third kind of potential treatment: HIV harm reduction
Memory T cells do not recognise circulating HIV in late infection
Other news
Chiron halts major IL-2 study, for business reasons
EU increases powers, and speeds up actions, of the European medicines agency
Zinc treatment for diarrhoea reduces child deaths
On the web
Post-meeting coverage of the 42nd ICAAC
AIDS-related malignancies in the era of HAART
Screening for and treatment of anal intraepithelial neoplasia
Coping with lipodystrophy’s emotional toll
Beyond HAART: a closer look at immune therapies
Digging deeper at the resistance workshop
Medscape conference coverage
Anaemia, neutropenia, and thrombocytopenia: pathogenesis and evolving treatment options in HIV-infected patients
Comprehensive health care for people infected with HIV in developing countries BMJ 2002;325:954-957
Anti-R7V antibodies may protect some HIV-infected patients from developing AIDS: a conversation with Jean-Claude Chermann
Combining saquinavir with lopinavir/ritonavir?
Glossary of HIV/AIDS-Related Terms, 4th ed
HIV and Its Treatment: What You Should Know, 2nd edition
PDFs
Volume 3 Number 10 December 2002 PDF
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate